In experiments using mouse lymphoma cell lines (H11, A20, and BL3750), ibrutinib enhanced the anti-tumor immune response induced by intratumoral injection of a toll like receptor 9 (TLR9) ligand, and promoted T cell-dependent tumor regression (Sagiv-Barfi et al., 2015). Here, TLR9 is linked to neoplasm.